<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893242</url>
  </required_header>
  <id_info>
    <org_study_id>BC28504</org_study_id>
    <secondary_id>2013-000088-10</secondary_id>
    <nct_id>NCT01893242</nct_id>
  </id_info>
  <brief_title>A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)</brief_title>
  <official_title>A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE THE RISK OF END STAGE RENAL DISEASE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ALERENAL STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled study will evaluate the potential of&#xD;
      aleglitazar to reduce the risk of end stage renal disease and cardiovascular mortality in&#xD;
      patients with type 2 diabetes mellitus and chronic kidney disease. Patients will be&#xD;
      randomized to receive oral daily doses of aleglitazar or matching placebo. The anticipated&#xD;
      time on study treatment is approximately 3 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death</measure>
    <time_frame>Approximately 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of any component of major adverse cardiovascular event composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)</measure>
    <time_frame>Approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of any component of macrovascular composite (CV death, non fatal myocardial infarction, hospitalization for unstable angina, non fatal stroke)</measure>
    <time_frame>Approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality</measure>
    <time_frame>Approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus Type 2, Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Aleglitazar Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aleglitazar</intervention_name>
    <description>Aleglitazar 150 mcg oral doses, once a day for approximately 3 years</description>
    <arm_group_label>Aleglitazar Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to aleglitazar, once a day for approximately 3 years</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients &gt;= 18 years of age at screening&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus Type 2&#xD;
&#xD;
          -  Glycosylated hemoglobin A1C (HbA1C) &lt; 10% at screening&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &gt;=30 and &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
          -  Urinary albumin-to-creatinine ratio (UACR) &gt;=500 and &lt; 5000 mg/g&#xD;
&#xD;
          -  Treatment with either angiotensin converting enzyme inhibitor or angiotensin II&#xD;
             receptor blocker for at least three months prior to screening&#xD;
&#xD;
          -  Women of child-bearing potential using a highly effective birth control method must be&#xD;
             willing to use the same method of contraception during the entire course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with a PPARgamma agonist and/or PPARalpha agonist in the last 12 weeks&#xD;
             screening&#xD;
&#xD;
          -  Prior intolerance to a TDZ or fibrate&#xD;
&#xD;
          -  Previous participation in a trial with aleglitazar&#xD;
&#xD;
          -  Diagnosis or history of other types of diabetes&#xD;
&#xD;
          -  Diagnosis or history of acute metabolic diabetic complications within the past 6&#xD;
             months&#xD;
&#xD;
          -  Known primary glomerulonephritis, secondary glomerulonephritis other than diabetic&#xD;
             nephropathy or polycystic kidney disease&#xD;
&#xD;
          -  Diagnosed acute kidney injury or dialysis within 12 weeks prior to screening&#xD;
&#xD;
          -  Poorly controlled hypertension (systolic blood pressure &gt; 160 mmHg and/or diastolic&#xD;
             blood pressure &gt; 100 mmHg at baseline)&#xD;
&#xD;
          -  Known secondary hypertension due to renal artery stenosis, primary aldosteronism, or&#xD;
             pheochromocytoma&#xD;
&#xD;
          -  History of myocardial infarction or stroke in the past 12 weeks prior to screening&#xD;
&#xD;
          -  Symptomatic congestive heart failure NYHA class II-IV at baseline or heart failure&#xD;
             leading to hospitalization within the 12 months prior to screening&#xD;
&#xD;
          -  Diagnosed and/or treated malignancy (except for treated cases of basal cell skin&#xD;
             cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5&#xD;
             years&#xD;
&#xD;
          -  Inadequate liver and hematological function&#xD;
&#xD;
          -  Chronic treatment with immunosuppressive therapy&#xD;
&#xD;
          -  Women who are pregnant, intending to become pregnant during the study period,&#xD;
             currently lactating females, or women of child-bearing potential not using highly&#xD;
             effective birth control methods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

